Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
NCT00729612
Completed
RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase II trial is studying how well paclitaxel albumin-stabilized nanoparticle formulation given together with carboplatin works in treating patients with stage IIIB... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
03/06/2018
Locations: Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Lung Cancer
Register for Updates
Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
NCT01280058
Completed
This phase II trial studies how well carboplatin and paclitaxel with or without viral therapy works in treating patients with pancreatic cancer that has come back or has spread to other places in the body. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Viral therapy may be able to kill tumor cells without damaging normal cells... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/08/2018
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Pancreatic Acinar Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage IV Pancreatic Cancer
Register for Updates
Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian
NCT01219777
Completed
The purpose of this study is to determine the maximum tolerated dose (MTD) of intravenous weekly paclitaxel given with intravenous carboplatin and bevacizumab in patients with epithelial ovarian, primary peritoneal, or fallopian tube carcinoma that are to receive neoadjuvant chemotherapy (prior to surgical cytoreduction). Patients will then undergo surgery which will allow an objective measure of response to the above regimen as well as assessment of surgical outcomes.
Gender:
FEMALE
Ages:
Between 18 years and 90 years
Trial Updated:
02/07/2018
Locations: The Ohio State University Medical Center, Columbus, Ohio
Conditions: Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
Register for Updates
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
NCT00499252
Completed
This phase II trial is studying the side effects and how well paclitaxel albumin-stabilized nanoparticle formulation works in treating patients with recurrent or persistent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer. Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Gender:
FEMALE
Ages:
All
Trial Updated:
12/14/2017
Locations: Riverside Methodist Hospital, Columbus, Ohio +1 locations
Conditions: Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma
Register for Updates
Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung Cancer
NCT00866528
Completed
The Phase I part of the study will identify the doses of pazopanib and paclitaxel that can be administered safely in combination. The Phase II part of the study will not be progressed as documented in Protocol Amendment 01.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/08/2017
Locations: GSK Investigational Site, Columbus, Ohio
Conditions: Lung Cancer, Non-Small Cell
Register for Updates
A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach
NCT01774851
Terminated
To determine whether the combination of MM-111 plus paclitaxel and trastuzumab is more effective than paclitaxel and trastuzumab alone
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/19/2017
Locations: Not set, Cleveland, Ohio +1 locations
Conditions: HER-2 Gene Amplification, Esophagus Cancer, Gastroesophageal Junction Cancer, Stomach Cancer
Register for Updates
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
NCT00789581
Completed
This is a randomized, Phase III, open-label, multicenter study.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/13/2017
Locations: Oncology Hematology Care, Cincinnati, Ohio +3 locations
Conditions: Breast Cancer
Register for Updates
S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer
NCT00856492
Completed
RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, doxorubicin, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Colony-stimulating factors, such as pegfilgrastim, may increase the number of immune cells found in bone marrow or peripheral blood and may help the immune system recover from the side effects of chemotherapy. Monoclonal antibodies, such as... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/23/2017
Locations: Summa Center for Cancer Care at Akron City Hospital, Akron, Ohio +50 locations
Conditions: Breast Cancer
Register for Updates
Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer
NCT00041119
Completed
This randomized phase III trial studies cyclophosphamide and doxorubicin hydrochloride compared with paclitaxel as adjuvant therapy in treating breast cancer in women with 0-3 positive axillary lymph nodes. Giving additional cancer treatment after surgery may help to lower the risk that the cancer will come back (adjuvant therapy). Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by k... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/12/2017
Locations: Summa Center for Cancer Care at Akron City Hospital, Akron, Ohio +53 locations
Conditions: Breast Cancer
Register for Updates
Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma
NCT00976573
Completed
This randomized phase II trial is studying how well carboplatin, paclitaxel, and bevacizumab work when given with or without everolimus in treating patients with malignant melanoma that has spread from where it started to other places in the body. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, may block the ability o... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/07/2017
Locations: Wood County Oncology Center, Bowling Green, Ohio +40 locations
Conditions: Melanoma (Skin)
Register for Updates
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
NCT01493505
Terminated
The purpose of this study is to determine whether AMG 386 or AMG 386 Placebo in combination with Paclitaxel and Carboplatin are effective in the treatment of ovarian cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/22/2017
Locations: Research Site, Akron, Ohio +11 locations
Conditions: Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
Register for Updates
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation
NCT01572727
Completed
This study evaluated whether the addition of daily BKM120 to weekly paclitaxel was effective and safe in treating patients with HER2- locally advanced or metastatic breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/27/2017
Locations: Ohio State Comprehensive Cancer Center/James Cancer Hospital SC-1, Columbus, Ohio
Conditions: Breast Cancer
Register for Updates